Brexanolone for postpartum depression
Autor: | Timothy C. Hutcherson, Nicole E. Cieri-Hutcherson, Meaghan F Gosciak |
---|---|
Rok vydání: | 2020 |
Předmět: |
Postpartum depression
medicine.medical_specialty Risk Evaluation and Mitigation Pregnanolone Placebo Severity of Illness Index law.invention Depression Postpartum 03 medical and health sciences 0302 clinical medicine Randomized controlled trial Pregnancy law Internal medicine medicine Humans Major depressive episode Adverse effect Depression (differential diagnoses) Randomized Controlled Trials as Topic Psychiatric Status Rating Scales Pharmacology 030219 obstetrics & reproductive medicine business.industry Health Policy beta-Cyclodextrins Hamilton Rating Scale for Depression medicine.disease Antidepressive Agents Clinical trial Drug Combinations Female medicine.symptom business 030217 neurology & neurosurgery |
Zdroj: | American Journal of Health-System Pharmacy. 77:336-345 |
ISSN: | 1535-2900 1079-2082 |
DOI: | 10.1093/ajhp/zxz333 |
Popis: | PurposePostpartum depression (PPD) is defined as a major depressive episode occurring during pregnancy or within 4 weeks of delivery that may have significant consequences for mother and infant. Antidepressants are used to treat PPD, but their effectiveness may be limited by a slow time to peak effect. Brexanolone is Food and Drug Administration–approved for the management of PPD; its use requires patient participation in a risk evaluation and mitigation strategies (REMS) program. This review evaluates the efficacy and safety of brexanolone in PPD.SummaryFour completed studies, 1 quasi-experimental study and 3 randomized controlled trials (RCTs), were reviewed. Females who had moderate or severe PPD during the third trimester or within 4 weeks of delivery and were less than 6 months postpartum at initiation of therapy were included. Improvement in Hamilton Rating Scale for Depression (HAM-D) scores was assessed in addition to safety outcomes and scores on other depression rating scales. All studies demonstrated statistical improvement in HAM-D scores from baseline with brexanolone vs placebo use at the end of infusions (ie, hour 60). Results with regard to sustained HAM-D score improvements were mixed in the RCTs at 30-day follow-up. The most frequent adverse events in brexanolone-treated patients were sedation, dizziness, somnolence, and headache. The severe or serious adverse effect of presyncope, syncope, or loss of consciousness was reported by 4% of participants.ConclusionWith a rapid onset of action, brexanolone could be considered advantageous over traditional therapies for PPD in patients for whom a rapid response is required due to severity of disease. Significant concerns remain regarding sustained effect and use in patients outside of the clinical trial setting. |
Databáze: | OpenAIRE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |